Last reviewed · How we verify
GBS glycoconjugate vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
GBS glycoconjugate vaccine (GBS glycoconjugate vaccine) — Novartis Vaccines.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GBS glycoconjugate vaccine TARGET | GBS glycoconjugate vaccine | Novartis Vaccines | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GBS glycoconjugate vaccine CI watch — RSS
- GBS glycoconjugate vaccine CI watch — Atom
- GBS glycoconjugate vaccine CI watch — JSON
- GBS glycoconjugate vaccine alone — RSS
Cite this brief
Drug Landscape (2026). GBS glycoconjugate vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/gbs-glycoconjugate-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab